FibroBiologics Inc. (NASDAQ:FBLG – Get Free Report) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 237,640 shares, a growth of 100.7% from the April 30th total of 118,414 shares. Currently, 5.0% of the shares of the stock are sold short. Based on an average daily volume of 563,635 shares, the days-to-cover ratio is currently 0.4 days.
Hedge Funds Weigh In On FibroBiologics
Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new position in FibroBiologics during the first quarter worth $29,000. XTX Topco Ltd increased its holdings in FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after buying an additional 28,276 shares during the last quarter. AMG National Trust Bank acquired a new position in FibroBiologics during the fourth quarter worth $31,000. Jane Street Group LLC acquired a new position in FibroBiologics during the fourth quarter worth $34,000. Finally, Marshall Wace LLP acquired a new position in FibroBiologics during the second quarter worth $49,000.
Analyst Ratings Changes
Several research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research note on Thursday, April 16th. Maxim Group lowered shares of FibroBiologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. Wall Street Zen raised shares of FibroBiologics to a “sell” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $74.00.
FibroBiologics Trading Down 3.4%
Shares of NASDAQ FBLG traded down $0.04 during midday trading on Monday, reaching $1.12. The company’s stock had a trading volume of 90,128 shares, compared to its average volume of 295,362. The stock has a market capitalization of $5.84 million, a price-to-earnings ratio of -0.16 and a beta of 1.13. FibroBiologics has a fifty-two week low of $0.95 and a fifty-two week high of $19.80. The stock has a 50 day simple moving average of $1.80 and a 200-day simple moving average of $4.53.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.33) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.33). As a group, equities analysts anticipate that FibroBiologics will post -4.41 EPS for the current year.
About FibroBiologics
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Featured Stories
- Five stocks we like better than FibroBiologics
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
